Home » Topics » Regulatory » EMA

EMA
RSS

EMA accepts Tagrisso submission in first-line EGFR-mutated NSCLC

Nov. 28, 2017

EMA accepts Macrilen MAA for adult growth hormone deficiency

Nov. 28, 2017

EMA launches improved version of EudraVigilance system for safety monitoring

Nov. 22, 2017

EMA announces relocation to the Netherlands

Nov. 21, 2017

Orexo's Zubsolv approved for opioid dependence in Europe

Nov. 21, 2017

bb-2121 receives FDA breakthrough therapy and EMA PRIME designations

Nov. 17, 2017

Marketing applications for volanesorsen accepted in U.S., E.U. and Canada

Nov. 16, 2017

EMA grants Motrem access to PRIME scheme for septic shock

Nov. 15, 2017

EMA's CHMP issues positive opinion on Adcetris for CTCL

Nov. 15, 2017

EMA committee supports approval of Endoceutics' Intrarosa

Nov. 15, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...